» Articles » PMID: 36400403

Discovery of a Potent GIPR Peptide Antagonist That is Effective in Rodent and Human Systems

Abstract

Objective: Glucose-dependent insulinotropic polypeptide (GIP) is one of the two major incretin factors that regulate metabolic homeostasis. Genetic ablation of its receptor (GIPR) in mice confers protection against diet-induced obesity (DIO), while GIPR neutralizing antibodies produce additive weight reduction when combined with GLP-1R agonists in preclinical models and clinical trials. Conversely, GIPR agonists have been shown to promote weight loss in rodents, while dual GLP-1R/GIPR agonists have proven superior to GLP-1R monoagonists for weight reduction in clinical trials. We sought to develop a long-acting, specific GIPR peptide antagonist as a tool compound suitable for investigating GIPR pharmacology in both rodent and human systems.

Methods: We report a structure-activity relationship of GIPR peptide antagonists based on the human and mouse GIP sequences with fatty acid-based protraction. We assessed these compounds in vitro, in vivo in DIO mice, and ex vivo in islets from human donors.

Results: We report the discovery of a GIP palmitoylated analogue, [N-Ac, L14, R18, E21] hGIP-K11 (γE-C16), which potently inhibits in vitro GIP-mediated cAMP generation at both the hGIPR and mGIPR. In vivo, this peptide effectively blocks GIP-mediated reductions in glycemia in response to exogenous and endogenous GIP and displays a circulating pharmacokinetic profile amenable for once-daily dosing in rodents. Co-administration with the GLP-1R agonist semaglutide and this GIPR peptide antagonist potentiates weight loss compared to semaglutide alone. Finally, this antagonist inhibits GIP- but not GLP-1-stimulated insulin secretion in intact human islets.

Conclusions: Our work demonstrates the discovery of a potent, specific, and long-acting GIPR peptide antagonist that effectively blocks GIP action in vitro, ex vivo in human islets, and in vivo in mice while producing additive weight-loss when combined with a GLP-1R agonist in DIO mice.

Citing Articles

Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation.

Davies I, Adriaenssens A, Scott W, Carling D, Murphy K, Minnion J Mol Metab. 2025; 92:102094.

PMID: 39788289 PMC: 11786100. DOI: 10.1016/j.molmet.2025.102094.


Transforming obesity: The advancement of multi-receptor drugs.

Kusminski C, Perez-Tilve D, Muller T, DiMarchi R, Tschop M, Scherer P Cell. 2024; 187(15):3829-3853.

PMID: 39059360 PMC: 11286204. DOI: 10.1016/j.cell.2024.06.003.


Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?.

Lafferty R, Flatt P, Gault V, Irwin N J Endocrinol. 2024; 262(2).

PMID: 38861364 PMC: 11301427. DOI: 10.1530/JOE-23-0339.


Effect of gut hormones on bone metabolism and their possible mechanisms in the treatment of osteoporosis.

Liu H, Xiao H, Lin S, Zhou H, Cheng Y, Xie B Front Pharmacol. 2024; 15:1372399.

PMID: 38725663 PMC: 11079205. DOI: 10.3389/fphar.2024.1372399.


Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature.

Chrysavgis L, Kazanas S, Bafa K, Rozani S, Koloutsou M, Cholongitas E Int J Mol Sci. 2024; 25(7).

PMID: 38612640 PMC: 11012092. DOI: 10.3390/ijms25073832.